Skip to main content

Month: June 2025

TransUnion Appoints Alicia Zuiker Chief Human Resources Officer

Dynamic leader will lead global talent strategies to drive growth and innovation CHICAGO, June 23, 2025 (GLOBE NEWSWIRE) — Alicia Zuiker has joined TransUnion (NYSE: TRU) as Executive Vice President, Chief Human Resources Officer (CHRO), effective June 23, 2025. Zuiker is an accomplished CHRO with deep experience leading global talent strategies across a range of relevant industries including financial services, digital enablement and technology. Her leadership has helped both mature and entrepreneurial companies achieve transformation and growth. In her new role at TransUnion, she will oversee TransUnion’s Human Resources and Communications functions, reporting to TransUnion President and CEO Chris Cartwright and serving on the executive leadership team. “We have bold aspirations for growth and innovation at TransUnion, and our...

Continue reading

Healthcare Realty Announces Reduction in Size of Board of Directors

NASHVILLE, Tenn., June 23, 2025 (GLOBE NEWSWIRE) — Healthcare Realty Trust Incorporated (NYSE:HR) (“Healthcare Realty” or the “Company”) today announced changes to its Board of Directors (“Board”), immediately reducing the size from 12 to 7 members. This reduction is part of a thoughtful effort to better align the size of the Board with other companies in the REIT industry, while maintaining the Board’s commitment to operating with best practices of corporate governance. In support of these efforts, five directors, Nancy Agee, Ajay Gupta, James Kilroy, Peter Lyle, and Christann Vasquez voluntarily retired from the Board, effective June 18, 2025. The Board’s independent chairman, Thomas Bohjalian said, “I would like to thank the retiring directors for their service and contributions to the Company, as well as their support and professionalism...

Continue reading

Global Net Lease Successfully Closes Third and Final Phase of Multi-Tenant Portfolio Sale

— Sale of 12 Properties Generates Approximately $313 Million in Gross Proceeds — Portfolio Sale Completed; Accelerates Deleveraging Plan and Transforms GNL to Single-Tenant Net Lease REIT NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) — Global Net Lease, Inc. (NYSE: GNL) (“GNL” or the “Company”) announced that it has completed the final phase of its multi-tenant portfolio sale to RCG Ventures, LLC on June 18, 2025, including 12 encumbered properties. This third phase generated approximately $313 million in gross proceeds1, bringing total gross proceeds from the portfolio sale to $1.8 billion2. GNL plans on using the incremental net proceeds from the third phase of the multi-tenant portfolio sale to further reduce leverage by paying down the outstanding balance on GNL’s Revolving Credit Facility. The multi-tenant portfolio sale simplifies...

Continue reading

Sydbank A/S share buyback programme: transactions in week 25

        Company Announcement No 28/2025Peberlyk 46200 AabenraaDenmark Tel +45 74 37 37 37Fax +45 74 37 35 36 Sydbank A/SCVR No DK 12626509, Aabenraasydbank.dk23 June 2025  Dear Sirs Sydbank A/S share buyback programme: transactions in week 25On 26 February 2025 Sydbank A/S announced a share buyback programme of DKK 1,350m. The share buyback programme commenced on 3 March 2025 and will be completed by 31 January 2026. The purpose of the share buyback programme is to reduce the share capital of Sydbank A/S and the programme is executed in compliance with the provisions of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 and Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016, collectively referred to as the Safe Harbour rules. The following transactions have been made under...

Continue reading

European Medicines Agency Recommends Market Approval of AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept)

REYKJAVIK, Iceland and LONDON, June 23, 2025 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human use (CHMP) adopted a positive opinion recommending approval for AVT06, Alvotech’s proposed biosimilar to Eylea® (aflibercept 2 mg). Based on a positive recommendation by CHMP, biosimilar medicines can be approved by the European Commission for marketing in the European Economic Area, that includes the 27 member states of the European Union, in addition to Norway, Iceland and...

Continue reading

Danske Bank share buy-back programme: transactions in week 25

 Company announcement no. 31 2025 Danske Bank Bernstorffsgade 40 DK-1577 København V Tel. + 45 33 44 00 00 23 June 2025 Page 1 of 1 Danske Bank share buy-back programme: transactions in week 25 On 7 February 2025, Danske Bank A/S announced a share buy-back programme for a total of DKK 5 billion, with a maximum of 45,000,000 shares, in the period from 10 February 2025 to 30 January 2026, at the latest, as described in company announcement no. 6 2025. The Programme is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 of the European Parliament and Council of 16 April 2014 (the “Market Abuse Regulation”) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (together with the Market Abuse Regulation, the “Safe Harbour Rules”). The following transactions on Nasdaq Copenhagen...

Continue reading

European Medicines Agency Recommends Market Approval of AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept)

REYKJAVIK, ICELAND and LONDON, UK (June 23, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human use (CHMP) adopted a positive opinion recommending approval for AVT06, Alvotech’s proposed biosimilar to Eylea® (aflibercept 2 mg). Based on a positive recommendation by CHMP, biosimilar medicines can be approved by the European Commission for marketing in the European Economic Area, that includes the 27 member states of the European Union, in addition to Norway, Iceland and Lichtenstein. “CHMP’s...

Continue reading

Official Launch of Virtune Coinbase 50 Index ETP Marked by Bell Ringing in Frankfurt

Stockholm, June 23, 2025 – Virtune, the Swedish regulated crypto asset manager, celebrated the official launch of its latest exchange-traded product, the Virtune Coinbase 50 Index ETP, with a ceremonial bell ringing at Deutsche Börse Xetra in Frankfurt on June 17, together with Coinbase. The ceremony, held together with Coinbase, marks a significant milestone in Virtune’s European expansion and reinforces its position as a leading issuer of regulated, physically backed crypto ETPs. The product is available to Swedish investors via online brokers such as Avanza and Montrose. Virtune listed the product on Xetra on June 2, 2025, making the Virtune Coinbase 50 Index ETP the first ETP in Europe to track the Coinbase 50 Europe Index – a broadly diversified index representing up to 50 leading crypto assets. The index is developed by Coinbase...

Continue reading

Share repurchase programme: Transactions of week 25 2025

The share repurchase programme runs as from 26 February 2025 and up to and including 30 January 2026 at the latest. In this period, Jyske Bank will acquire shares with a value of up to DKK 2.25 billion, cf. Corporate Announcement No. 3/2025 of 26 February 2025. The share repurchase programme is initiated and structured in compliance with the EU Commission Regulation No. 596/2014 of 16 April 2014, the so-called “Market Abuse Regulation”, and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (together with the Market Abuse Regulation, the “Safe Harbour Rules”). The following transactions have been made under the program:  Number of shares Average purchase price (DKK) Transaction value (DKK)Accumulated, previous announcement 1,025.529 541.18 554,995,99516 June 2025 15,000 636.39 9,545,91917 June...

Continue reading

LEADING EDGE MATERIALS’ INVESTOR UPDATE AND SIGNIFICANT ACTIVITIES

LEADING EDGE MATERIALS’ INVESTOR UPDATE ON SIGNIFICANT ACTIVITIES Vancouver, June 22, 2025 – Leading Edge Materials Corp. (“Leading Edge Materials” or the “Company”) (TSXV: LEM) (Nasdaq First North: LEMSE) (OTCQB: LEMIF) provides an investor update on significant activities. Overview – Becoming a European CRM producer Concerns about critical raw materials – security of supply, supply chain resilience and defence requirements – have been recurring themes at conferences attended by the Company in recent months, with Heavy Rare Earth Elements (“HREEs”) and natural graphite frequently mentioned; geopolitical uncertainty is the new norm and it is driving partnership, collaboration and greater levels of support for mining. On June 17, 2025, the G7 Critical Minerals Action Plan was announced focused on ‘diversifying the responsible...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.